Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
1(20%)
Results Posted
33%(1 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_2
1
20%
Ph phase_1
3
60%
Ph phase_3
1
20%

Phase Distribution

3

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
3(60.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(3)
Terminated(1)

Detailed Status

Completed3
Active, not recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
75.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (60.0%)
Phase 21 (20.0%)
Phase 31 (20.0%)

Trials by Status

active_not_recruiting120%
completed360%
terminated120%

Recent Activity

1 active trials
Showing 5 of 5
completedphase_1

A Study to Evaluate the Pharmacokinetics, Safety and Immunogenicity of BIIB800 Subcutaneously (SC) Compared to Actemra® in Healthy Male Participants

NCT06262477
active_not_recruitingphase_1

A Safety and Pharmacokinetics Study of Complarate (Tocilizumab Biosimilar Solution) and Actemra® in Healthy Volunteers

NCT06488521
terminatedphase_2

Pyrexia Management Using an IL-6 Antibody in BRAF+ Melanoma Patients Treated with Dabrafenib/ Trametinib +/- Immunotherapy

NCT04652258
completedphase_3

Comparison of Complarate® (Tocilizumab Biosimilar) and Actemra® in Patients With Rheumatoid Arthritis

NCT06475508
completedphase_1

A Safety and Pharmacokinetic Study of Complarate (Tocilizumab Biosimilar) and Actemra® in Healthy Volunteers

NCT06481202

Clinical Trials (5)

Showing 5 of 5 trials
NCT06262477Phase 1

A Study to Evaluate the Pharmacokinetics, Safety and Immunogenicity of BIIB800 Subcutaneously (SC) Compared to Actemra® in Healthy Male Participants

Completed
NCT06488521Phase 1

A Safety and Pharmacokinetics Study of Complarate (Tocilizumab Biosimilar Solution) and Actemra® in Healthy Volunteers

Active Not Recruiting
NCT04652258Phase 2

Pyrexia Management Using an IL-6 Antibody in BRAF+ Melanoma Patients Treated with Dabrafenib/ Trametinib +/- Immunotherapy

Terminated
NCT06475508Phase 3

Comparison of Complarate® (Tocilizumab Biosimilar) and Actemra® in Patients With Rheumatoid Arthritis

Completed
NCT06481202Phase 1

A Safety and Pharmacokinetic Study of Complarate (Tocilizumab Biosimilar) and Actemra® in Healthy Volunteers

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5